Related Experiment Video
Updated: Aug 18, 2025
14:35
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.6K
APELIN IN HEART FAILURE
Kamil Marczewski1, Natalia Gospodarczyk1, Alicja Gospodarczyk2
1DEPARTMENT OF EMERGENCY MEDICINE, MEDICAL UNIVERSITY OF SILESIA, POLAND.
Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|December 6, 2022
Summary
Apelin, an adipokine, plays a crucial role in cardiovascular health by lowering blood pressure and improving insulin sensitivity. Further research may unlock its potential for treating heart failure and metabolic diseases.
Area of Science:
- Cardiovascular Biology
- Metabolic Disease Research
- Endocrinology
Background:
- Apelin is a protein encoded by the APLN gene, acting as a ligand for the APJ receptor.
- Expressed in various tissues, highest concentrations are found in the endocardium and vascular endothelium.
- Apelin is classified as an adipokine due to its secretion by adipocytes.
Purpose of the Study:
- To summarize the biological functions and tissue distribution of apelin.
- To highlight apelin's role in cardiovascular regulation and metabolic homeostasis.
- To discuss the potential therapeutic implications of apelin in disease treatment.
Main Methods:
- Literature review of studies on apelin's biological activity and expression.
- Analysis of apelin's effects on the cardiovascular system and glucose metabolism.
- Synthesis of current understanding regarding apelin's role in disease pathogenesis.
Main Results:
- Apelin exhibits a positive inotropic effect in myocardial tissue and counteracts the renin-angiotensin-aldosterone system, lowering blood pressure.
- Apelin enhances cellular insulin sensitivity and improves glucose tolerance, suggesting a role in metabolic disease.
- Elevated apelin production in adipose tissue is observed in obesity.
Conclusions:
- Apelin is a significant factor in cardiovascular homeostasis and metabolic health.
- Its potential therapeutic applications in heart failure, hypertension, and type 2 diabetes warrant further investigation.
- Apelin's multifaceted roles underscore its importance in physiological and pathological processes.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
482
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
482
01:29Heart Failure II: Pathophysiology
26
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
26
01:22Heart Failure Drugs: β-Blockers
412
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
412
01:17Pathophysiology of Heart Failure
1.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
01:30Heart Failure V: Medical Management
19
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
01:22Heart Failure VI: Adjunct Therapies
24
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
24